is a privately held ophthalmic company that develops and markets new ways for ophthalmologists to effectively treat refractive errors with its proprietary Conductive Keratoplasty
He has served as a clinical investigator for many LASIK studies, Conductive Keratoplasty
(CK) and the Artisan Phakic Introcular Lens (IOL).
Kanner joined the company last year to assist in commercializing the ViewPoint(TM) CK System, a device used to perform Conductive Keratoplasty for the treatment of hyperopia.
Refractec is currently conducting Phase III clinical trials in the United States for Conductive Keratoplasty (CK), a minimally invasive non-laser approach for correcting low to moderate hyperopia.
investigators in anticipation of expanding their Phase III clinical trials of Conductive Keratoplasty
Phase III IDE study of Conductive Keratoplasty for vision correction.
will present his Conductive Keratoplasty data at the 1999 Fall World Refractive Surgery Symposium (ISRS) in Orlando, Fla.
announced that it has initiated numerous international Post-Marketing Studies using Conductive Keratoplasty
(CK) to treat Hyperopia, Presbyopia, Astigmatism and Retreatment of patients with prior alternative refractive procedures.